ArticleScientific reports2025
Target sequence of single cells captured by a polymeric microfluidic device.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Detecting rare circulating tumor cells (CTCs), malignant cells of primary site origin, in the bloodstream is difficult. We previously constructed a polymeric microfluidic device with high capture efficiency for lung cancer cell lines using antibodies against the epithelial cell adhesion molecule (EpCAM). In this study, we investigated a method for extracting DNA from single cells captured in a microfluidic device and performed targeted sequencing using the Cancer Hotspot Panel v2. Additionally, we employed a fixation method, which enabled more efficient sequencing of the EpCAM-chip-captured cells than existing fixation methods. We used blood samples obtained from three patients with lung cancer to assess the clinical applicability of our method. Directly sequenced samples revealed better coverage uniformity than samples subjected to whole-genome sequencing. Direct sequencing of cells fixed with preserver fluid and 100% ethanol was performed accurately with high coverage uniformity. Our method demonstrated a sensitivity of 99.4%, specificity of 99.5%, and area under the curve of 1 (allele frequency cut-off, 18%). Our approach suggests that single cells captured in a microfluidic device are sufficient for genetic mutation analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.